Nanoparticles Target Tuberculosis-Infected Cells in the Lung

Researchers are urgently seeking better ways to treat infections as antimicrobial resistance spreads and new threats emerge. One promising idea is to use tiny engineered particles to carry drugs directly to the sites of infection, reducing side effects and improving effectiveness. In the lungs, this approach can be delivered by breathing in aerosolized nanocarriers so medicine concentrates where it is needed most. In work led by Arnaud Machelart, scientists tested this strategy in a laboratory model of pulmonary infection. They introduced poly(lactic-co-glycolic acid) (PLGA) nanoparticles into the lungs of Mycobacterium tuberculosis–infected mice using pulmonary administration. The team then looked at where the particles went in the lung and which cells interacted with them. They focused on alveolar macrophages, the immune cells in the air sacs that are the primary host cells for the tuberculosis bacteria. The study set out to see whether these particles simply spread broadly through the lung or whether they had a tendency to concentrate in the infected cells that harbor the pathogen.

Using the inhaled route, the PLGA nanoparticles were found broadly throughout the lung but showed a clear preference for interacting with alveolar macrophages, the cells that Mycobacterium tuberculosis infects. Crucially, the investigators observed that macrophages carrying the bacteria internalized significantly more nanoparticles than neighboring uninfected macrophages. This enrichment in infected cells occurred regardless of the virulence or viability of the bacteria present, indicating the effect was linked to the infected state rather than active or more aggressive strains. To probe possible biological reasons for this selective uptake, the team performed transcriptomic analysis and identified a set of 21 commonly modulated genes that may underlie the increased nanoparticle internalization. Although the abstract does not list these gene names, the transcriptomic approach points to specific molecular changes in infected macrophages that could explain why they take up more PLGA nanoparticles after pulmonary administration and exposure to aerosolized nanocarriers.

The findings highlight a striking property of nanocarriers: their ability to accumulate selectively in infected host cells. For pulmonary infections like tuberculosis, this selective uptake could be a powerful way to concentrate antimicrobials inside the very cells that shelter the bacteria, potentially boosting drug potency where it matters and limiting systemic exposure that causes side effects. By demonstrating that infected alveolar macrophages take up more poly(lactic-co-glycolic acid) (PLGA) nanoparticles and by identifying 21 genes commonly altered in these cells, the study provides a biological rationale to design targeted delivery systems. This could influence future development of inhaled nanoparticle therapies and guide researchers to modify particle composition or surface features to exploit the natural tendency of infected macrophages to internalize them. Ultimately, these insights form a foundation for further work on targeted antimicrobial delivery to improve treatment outcomes for pulmonary Mycobacterium tuberculosis infections while minimizing harm to the rest of the body.